Intravenous gammaglobulin-associated renal impairment reported to the FDA: 2004-2009

Clinical Nephrology

Volumn 76, Issue 5, 2011, Pages 365-372

  Lin, R Y ^a,b,c   Rodriguez Baez, G ^b,c   Bhargave, G A ^b,c   Lin, H ^d  

^a NEW YORK DOWNTOWN HOSPITAL   (United States)

^b ST VINCENT S HOSPITAL   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d Stuyvesant High School   (United States)

Author keywords

Fda; Hemodialysis; Renal impairment; Sucrose

Indexed keywords

GLYCINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MALTOSE; PROLINE; SORBITOL; SUCROSE;

AGING; ANAPHYLAXIS; ARTICLE; CLINICAL ASSESSMENT; DEMOGRAPHY; DIABETES MELLITUS; DRUG APPROVAL; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC DISEASE; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; NEUROMUSCULAR DISEASE; PREDICTION; SYSTEMATIC REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CHI-SQUARE DISTRIBUTION; FEMALE; GAMMA-GLOBULINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 82155173035     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106824     Document Type: Article

References (21)

1. U.S. Food and Drug Administration. Dear Doctor Letter IMPORTANT DRUG WARNING - Potential risk of ACUTE RENAL FAILURE reported to be associated with administration of Immune Globulin Intravenous (Human). http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm105901.htm (last accessed 1/3/09).
2. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009; 158 (Suppl 1): 23-33.
3. Stegall MD, Gloor JM. Deciphering antibodymediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant. 2010; 15: 8-10.
4. Knowles S, Shear NH. Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Ther. 2009; 22: 441-451.
5. Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity. 2009; 42: 553-560.
6. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. Curr Opin Neurol. 2009; 22: 480-485.
7. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation. 2009; 88: 1-6.
8. Galeotti C, Maddur MS, Kazatchkine MD, Mouthon L, Kaveri SV. Intravenous immunoglobulins in autoimmune and inflammatory disorders: beyond a simple substitution. Transfus Clin Biol. 2009; 16: 75-79.
9. U.S. Food and Drug Administration. User Fee Billable Biologic Products and Potencies Approved Under Section 351 of the PHS Act http://www.fda.gov/AboutFDA/CentersOffices/CBER/ucm122936.htm (last accessed 3/16/10).
10. The Adverse Event Reporting System (AERS) Latest Quarterly Data Files. http://www.fda.gov/cder/aers/extract.htm (last accessed 1/3/09).
11. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999; 20: 109-117.
12. MedDRA FAQ. https://meddramsso.com/public_ faq_meddra.asp (last accessed 1/3/10).
13. U.S. Office of Special Counsel. Freedom of Information Act (FOIA) Handbook http://www.osc.gov/foia.htm (last accessed 1/30/10).
14. Talecris Biotherapeutics. The history of Talecris. http://www.talecris.com/talecris-history.htm (last accessed 1/3/10).
15. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005; 29: 173-184.
16. Clarkson MR, Friedewald JJ, Eustace JA, Rabb H. Acute kidney injury in Brenner & Rector's The Kidney. 8th ed. Saunders: Philadelphia; 2008. p. 961.
17. Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. Am J Gastroenterol. 2001; 96: 3428-3431.
18. Manlhiot C, Tyrrell PN, Liang L, Atkinson AR, Lau W, Feldman BM. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008; 121: 626-630. Published online February 25, 2008.
19. Milch CE, Salem DN, Pauker SG, Lundquist TG, Kumar S, Chen J. Voluntary electronic reporting of medical errors and adverse events. An analysis of 92,547 reports from 26 acute care hospitals. J Gen Intern Med. 2006; 21: 165-170.
20. U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation Analysis of supply, distribution, demand, and access issues associated with immune globulin intravenous (IGIV) http://aspe.hhs.gov/sp/reports/2007/IGIV/report.pdf (last accessed Sept 9, 2009).
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612.